Sweden's Ambea Q3 sales rise on higher occupancy, operational improvements

By Reuters News


Overview

  • Sweden care provider's Q3 net sales rose 8% yr/yr to SEK 4,447 mln

  • Adjusted EPS for Q3 rose to SEK 4.86 from SEK 3.83 yr/yr

  • Company completed Humana acquisition after quarter end


Outlook

  • Company sees growing demand for care services across the Nordic region

  • Ambea expanding capacity to address anticipated future care needs

  • Company has started integrating Humana acquisition, aiming for operational synergies


Result Drivers

  • HIGHER OCCUPANCY - Co said increased occupancy rates across operations drove earnings growth

  • STAFFING EFFICIENCY - Co said improved staffing efficiency contributed to profitability, notably in Nytida and Stendi

  • ACQUISITIONS - Co said acquisitions, including Validia and Humana, supported growth and expansion


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Miss*

SEK 4.45 bln

SEK 4.49 bln (2 Analysts)

Q3 EBIT

SEK 619 mln

Q3 EBITA

SEK 645 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Ambea publ AB is SEK216.50, about 16.6% above its November 3 closing price of SEK185.60

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago


Reuters Recommended Reads

  • Nov 3 - LTC Properties Q3 revenue surges on SHOP acquisitions

  • Nov 3 - Omega Healthcare Investors Q3 AFFO rises, full-year guidance raised

  • Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.